• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    5/11/26 8:52:04 AM ET
    $GRAL
    Medical Specialities
    Health Care
    Get the next $GRAL alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    GRAIL, Inc.

    (Name of Issuer)


    Common Stock, par value $0.001 per share (the "Shares")

    (Title of Class of Securities)




    384747101

    (CUSIP Number)
    03/31/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    249,315.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    249,315.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    249,315.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.6 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital Institutional Partners, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    267,221.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    267,221.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    267,221.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.7 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital Institutional Partners II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CALIFORNIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    67,446.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    67,446.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    67,446.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital Institutional Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    50,555.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    50,555.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    50,555.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Four Crossings Institutional Partners V, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    57,183.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    57,183.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    57,183.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital Offshore Investors II, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    595,840.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    595,840.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    595,840.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital (AM) Investors, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    34,045.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    34,045.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    34,045.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Capital F5 Master I, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    67,660.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    67,660.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    67,660.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Healthcare Partners Master, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,864,419.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,864,419.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,864,419.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Partners, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,186,024.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,186,024.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,186,024.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.7 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Institutional (GP) V, L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    57,183.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    57,183.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    57,183.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.1 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon F5 (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    67,660.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    67,660.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    67,660.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.2 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Farallon Healthcare Partners (GP), L.L.C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,864,419.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,864,419.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,864,419.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    4.5 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Dapice Joshua J.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Dreyfuss, Philip D.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Dunn Hannah E.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Gehani, Varun N.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Giauque, Nicolas
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    FRANCE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Husen, Avner A.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Kim, David T.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Linn, Michael G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Luo Patrick (Cheng)
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    CHINA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Roberts, Jr., Thomas G.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Saito Edric C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Short Daniel S.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Spokes, Andrew J. M.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED KINGDOM
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Warren, John R.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP Number(s):
    384747101


    1Names of Reporting Persons

    Wehrly, Mark C.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,253,684.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,253,684.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,253,684.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    GRAIL, Inc.
    (b)Address of issuer's principal executive offices:

    1525 O'Brien Drive, Menlo Park, California, 94025
    Item 2. 
    (a)Name of person filing:

    This Amendment No. 2 to Schedule 13G (this "Amendment") is filed by the entities and persons listed below, all of whom together are referred to herein as the "Reporting Persons." (i) Farallon Capital Partners, L.P., a California limited partnership ("FCP"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants (as defined in Item 4); (ii) Farallon Capital Institutional Partners, L.P., a California limited partnership ("FCIP"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (iii) Farallon Capital Institutional Partners II, L.P., a California limited partnership ("FCIP II"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (iv) Farallon Capital Institutional Partners III, L.P., a Delaware limited partnership ("FCIP III"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (v) Four Crossings Institutional Partners V, L.P., a Delaware limited partnership ("FCIP V"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (vi) Farallon Capital Offshore Investors II, L.P., a Cayman Islands exempted limited partnership ("FCOI II"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (vii) Farallon Capital (AM) Investors, L.P., a Delaware limited partnership ("FCAMI"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; (viii) Farallon Capital F5 Master I, L.P., a Cayman Islands exempted limited partnership ("F5MI"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants; and (ix) Farallon Healthcare Partners Master, L.P., a Cayman Islands exempted limited partnership ("FHPM"), with respect to the Shares held by it and the Shares that it currently has the right to acquire upon the exercise of Warrants. FCP, FCIP, FCIP II, FCIP III, FCIP V, FCOI II, FCAMI, F5MI and FHPM are together referred to herein as the "Farallon Funds." (x) Farallon Partners, L.L.C., a Delaware limited liability company (the "Farallon General Partner"), which is the general partner of each of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of each of the FCIP V General Partner (as defined below) and the FHPM General Partner (as defined below), with respect to the Shares held by each of the Farallon Funds other than F5MI and the Shares that each of the Farallon Funds other than F5MI currently has the right to acquire upon the exercise of Warrants. (xi) Farallon Institutional (GP) V, L.L.C., a Delaware limited liability company (the "FCIP V General Partner"), which is the general partner of FCIP V, with respect to the Shares held by FCIP V and the Shares that FCIP V currently has the right to acquire upon the exercise of Warrants. (xii) Farallon F5 (GP), L.L.C., a Delaware limited liability company (the "F5MI General Partner"), which is the general partner of F5MI, with respect to the Shares held by F5MI and the Shares that F5MI currently has the right to acquire upon the exercise of Warrants. (xiii) Farallon Healthcare Partners (GP), L.L.C., a Delaware limited liability company (the "FHPM General Partner"), which is the general partner of FHPM, with respect to the Shares held by FHPM and the Shares that FHPM currently has the right to acquire upon the exercise of Warrants. (xiv) The following persons, each of whom is a managing member or senior managing member, as the case may be, of the Farallon General Partner, and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, with respect to the Shares held by the Farallon Funds and the Shares that the Farallon Funds currently have the right to acquire upon the exercise of Warrants: Joshua J. Dapice ("Dapice"); Philip D. Dreyfuss ("Dreyfuss"); Hannah E. Dunn ("Dunn"); Varun N. Gehani ("Gehani"); Nicolas Giauque ("Giauque"); Avner A. Husen ("Husen"); David T. Kim ("Kim"); Michael G. Linn ("Linn"); Patrick (Cheng) Luo ("Luo"); Thomas G. Roberts, Jr. ("Roberts"); Edric C. Saito ("Saito"); Daniel S. Short ("Short"); Andrew J. M. Spokes ("Spokes"); John R. Warren ("Warren"); and Mark C. Wehrly ("Wehrly"). Dapice, Dreyfuss, Dunn, Gehani, Giauque, Husen, Kim, Linn, Luo, Roberts, Saito, Short, Spokes, Warren and Wehrly are together referred to herein as the "Farallon Individual Reporting Persons."
    (b)Address or principal business office or, if none, residence:

    The address of the principal business office of each of the Reporting Persons is c/o Farallon Capital Management, L.L.C., One Maritime Plaza, Suite 2100, San Francisco, California 94111.
    (c)Citizenship:

    The citizenship of each of the Farallon Funds, the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner is set forth above. Each of the Farallon Individual Reporting Persons, other than Giauque, Luo and Spokes, is a citizen of the United States. Giauque is a citizen of France. Luo is a citizen of China. Spokes is a citizen of the United Kingdom.
    (d)Title of class of securities:

    Common Stock, par value $0.001 per share (the "Shares")
    (e)CUSIP No.:

    384747101
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person. As of the date requiring the filing of this report, the Farallon Funds hold an aggregate of: (i) 2,682,663 Shares; and (ii) 571,021 Pre-Funded Common Stock Purchase Warrants (the "Warrants"), each of which is exercisable, subject to the Beneficial Ownership Limitation (as defined below), to purchase one Share. The terms of the Warrants provide that Warrants may not be exercised to the extent that, after giving effect to such exercise, the Reporting Persons would beneficially own, as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934, as amended, more than 9.99% of the Shares then issued and outstanding (the "Beneficial Ownership Limitation"). As of the date requiring the filing of this report, the Beneficial Ownership Limitation does not prevent the Farallon Funds from exercising any Warrants. Accordingly, in providing the beneficial ownership information set forth herein, the Reporting Persons have assumed that all of the aggregate 571,021 Warrants held by the Farallon Funds are exercisable within 60 days of the date hereof and therefore confer beneficial ownership of the underlying Shares. The Shares and Warrants reported hereby for the Farallon Funds are held directly by the Farallon Funds. The Farallon General Partner, as the general partner of FCP, FCIP, FCIP II, FCIP III, FCOI II and FCAMI and the sole member of the FCIP V General Partner and the FHPM General Partner, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds other than F5MI and the Shares that the Farallon Funds other than F5MI have the right to acquire upon the exercise of Warrants. The FCIP V General Partner, as the general partner of FCIP V, may be deemed to be a beneficial owner of all such Shares held by FCIP V and the Shares that FCIP V has the right to acquire upon the exercise of Warrants. The F5MI General Partner, as the general partner of F5MI, may be deemed to be a beneficial owner of all such Shares held by F5MI and the Shares that F5MI has the right to acquire upon the exercise of Warrants. The FHPM General Partner, as the general partner of FHPM, may be deemed to be a beneficial owner of all such Shares held by FHPM and the Shares that FHPM has the right to acquire upon the exercise of Warrants. Each of the Farallon Individual Reporting Persons, as a managing member or senior managing member, as the case may be, of the Farallon General Partner and a manager or senior manager, as the case may be, of the FCIP V General Partner, the F5MI General Partner and the FHPM General Partner, in each case with the power to exercise investment discretion, may be deemed to be a beneficial owner of all such Shares held by the Farallon Funds and the Shares that the Farallon Funds have the right to acquire upon the exercise of Warrants. Each of the Farallon General Partner, the FCIP V General Partner, the F5MI General Partner, the FHPM General Partner and the Farallon Individual Reporting Persons hereby disclaims any beneficial ownership of any such Shares.
    (b)Percent of class:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (ii) Shared power to vote or to direct the vote:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iii) Sole power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

     (iv) Shared power to dispose or to direct the disposition of:

    The information required by Items 4(a) - (c) and set forth in Rows 5 through 11 of the cover page for each Reporting Person is incorporated herein by reference for each such Reporting Person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Not Applicable
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.


    The Reporting Persons are filing this Schedule 13G pursuant to Section 240.13d-1(c). The Reporting Persons neither disclaim nor affirm the existence of a group among them. Each Reporting Person is a beneficial owner only of the securities reported by it on its cover page.
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Farallon Capital Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Farallon Capital Institutional Partners, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Farallon Capital Institutional Partners II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Farallon Capital Institutional Partners III, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Four Crossings Institutional Partners V, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:05/11/2026
     
    Farallon Capital Offshore Investors II, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Farallon Capital (AM) Investors, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member of its General Partner
    Date:05/11/2026
     
    Farallon Capital F5 Master I, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:05/11/2026
     
    Farallon Healthcare Partners Master, L.P.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager of its General Partner
    Date:05/11/2026
     
    Farallon Partners, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Managing Member
    Date:05/11/2026
     
    Farallon Institutional (GP) V, L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:05/11/2026
     
    Farallon F5 (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:05/11/2026
     
    Farallon Healthcare Partners (GP), L.L.C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, Manager
    Date:05/11/2026
     
    Dapice Joshua J.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Dreyfuss, Philip D.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Dunn Hannah E.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn
    Date:05/11/2026
     
    Gehani, Varun N.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Giauque, Nicolas
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Husen, Avner A.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Kim, David T.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Linn, Michael G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Luo Patrick (Cheng)
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Roberts, Jr., Thomas G.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Saito Edric C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Short Daniel S.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Spokes, Andrew J. M.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Warren, John R.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
     
    Wehrly, Mark C.
     
    Signature:/s/ Hannah E. Dunn
    Name/Title:Hannah E. Dunn, as attorney-in-fact
    Date:05/11/2026
    Exhibit Information

    Exhibit 1. Joint Acquisition Statement Pursuant to Section 240.13d-1(k) (previously filed)

    Get the next $GRAL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GRAL

    DatePrice TargetRatingAnalyst
    6/2/2026Peer Perform
    Wolfe Research
    4/10/2026$58.00Neutral
    Mizuho
    3/18/2026$65.00Hold → Buy
    TD Cowen
    2/19/2026$114.00Hold
    TD Cowen
    2/17/2026$113.00Outperform
    Robert W. Baird
    12/2/2025$110.00Equal-Weight
    Morgan Stanley
    11/12/2025$100.00Neutral → Buy
    Guggenheim
    4/21/2025$32.00Buy
    Canaccord Genuity
    More analyst ratings

    $GRAL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Ding Chun R bought $1,024,698 worth of shares (78,829 units at $13.00) and acquired $879,900 worth of shares (70,000 units at $12.57) (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    10/10/24 7:45:32 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    SEC Filings

    View All

    GRAIL Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - GRAIL, Inc. (0001699031) (Filer)

    6/1/26 4:07:27 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

    5/15/26 4:17:57 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by GRAIL Inc.

    SCHEDULE 13G/A - GRAIL, Inc. (0001699031) (Subject)

    5/11/26 8:52:04 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Ofman Joshua J. was granted 31,055 shares, increasing direct ownership by 8% to 402,271 units (SEC Form 4)

    4 - GRAIL, Inc. (0001699031) (Issuer)

    6/3/26 8:04:09 PM ET
    $GRAL
    Medical Specialities
    Health Care

    New insider Partridge Andrew John claimed ownership of 165,229 shares (SEC Form 3)

    3 - GRAIL, Inc. (0001699031) (Issuer)

    6/2/26 5:51:50 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form 4 filed by Summe Gregory L

    4 - GRAIL, Inc. (0001699031) (Issuer)

    4/17/26 4:06:58 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research resumed coverage on GRAIL

    Wolfe Research resumed coverage of GRAIL with a rating of Peer Perform

    6/2/26 8:33:04 AM ET
    $GRAL
    Medical Specialities
    Health Care

    Mizuho initiated coverage on GRAIL with a new price target

    Mizuho initiated coverage of GRAIL with a rating of Neutral and set a new price target of $58.00

    4/10/26 8:32:03 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL upgraded by TD Cowen with a new price target

    TD Cowen upgraded GRAIL from Hold to Buy and set a new price target of $65.00

    3/18/26 8:18:48 AM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    GRAIL Presents PATHFINDER 2 Results of More Than 35,000 Participants Showing the Galleri® Test Substantially Increased Cancer Detection With Robust Performance and Favorable Safety at 2026 ASCO Annual Meeting

    The Galleri Multi-Cancer Early Detection (MCED) Test Increased Cancer Detection 6.5 Fold When Added to Recommended Screenings for Breast, Colorectal, Cervical and Lung Cancer71% of the New Cancers Detected by the Galleri Test Were in Stages I-IIIMENLO PARK, Calif., May 31, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that positive performance and safety results from the analysis of the full 35,878 cohort of its registrational PATHFINDER 2 study are being presented during an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting[1]. Th

    5/31/26 8:00:00 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports Full Results From NHS-Galleri Trial Demonstrating Substantial Reduction in Stage IV Cancer Diagnoses at 2026 ASCO Annual Meeting

    No Reduction Observed in Combined Primary Endpoint of Stage III/IV Cancers in Aggregate; However, Decreases Observed Beyond the Prevalent Screening Round  Annual Galleri® Blood Test Reduced Stage IV Diagnoses of 12 Prespecified Cancers by 22% and 26% in the Second and Third Screening Rounds, RespectivelyGalleri Increased Cancer Detection Rate by Four-Fold When Added to Standard of Care Screening and Reduced Cancer Diagnosis Through Emergency Presentation by 25%Annual Testing With Galleri Increased Stage I-II Cancer Diagnoses by 16% When Added to Standard of CareGRAIL to Host Analyst Call From 2026 ASCO Annual Meeting MENLO PARK, Calif., May 30, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL),

    5/30/26 8:00:00 AM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    MENLO PARK, Calif., May 27, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 34,350 shares of GRAIL's common stock to 56 recently hired non-executive employees as an inducement material to their acceptance of employment with GRAIL. The employment inducement awards were granted under GRAIL's Inducement Equity Incentive Plan and related form of restricted stock award agreement in accordance with Nasdaq Listing Rule 5635(c)(4).

    5/27/26 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Leadership Updates

    Live Leadership Updates

    View All

    GRAIL Announces Retirement of CEO Bob Ragusa and Appointment of Josh Ofman, MD, MSHS, as Successor

    MENLO PARK, Calif., March 12, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that Bob Ragusa will retire as Chief Executive Officer, effective June 1, 2026. GRAIL's Board of Directors has appointed the Company's President, Josh Ofman, MD, MSHS, to serve as GRAIL's Chief Executive Officer upon Ragusa's retirement. In addition, Ofman has been appointed to GRAIL's Board of Directors, effective immediately. Ofman's appointment is the culmination of a long-term comprehensive succession planning process to ensure leadership continuity and strategic execution. Ragusa will remain on GRAIL's Board unti

    3/12/26 4:30:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Appoints Sarah Krevans to Board of Directors

    MENLO PARK, Calif., Oct. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced the appointment of Sarah Krevans to its Board of Directors, effective immediately. Ms. Krevans will also serve as a member of the Board's Audit Committee, Compensation Committee, and Nominating and Governance Committee. Following the appointment of Ms. Krevans, the Board will be composed of five directors, four of whom are independent. Ms. Krevans served as president and CEO of Sutter Health, a Northern

    10/21/24 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Wheels Up Announces Gregory Summe to Join Board of Directors

    Veteran Leader Brings Deep Strategic, Aviation, and Governance Experience to Boardroom ATLANTA, Aug. 8, 2024 /PRNewswire/ -- Wheels Up Experience Inc. (NYSE:UP) today announced that Gregory L. Summe, Managing Partner of Glen Capital Partners LLC, joined its Board of Directors, effective August 7. Summe fills the unexpired term of David Adelman, who is stepping down to focus on other professional pursuits. Summe's initial term as a Class II director will continue until the 2026 annual meeting of the Company's stockholders. He will serve on the Audit and Compensation Committees

    8/8/24 8:05:00 AM ET
    $AVTR
    $GRAL
    $NXPI
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical Specialities
    Health Care

    $GRAL
    Financials

    Live finance-specific insights

    View All

    GRAIL Reports First Quarter 2026 Financial Results

    Q1 Galleri® Revenue Grew 37% Year-Over-Year to $39.8 Million, and Test Volume Increased 50% to More Than 56,000Announced Plans to Integrate the Galleri Test Into Epic Electronic Health Record Platform to Expand Access NationwideNew Data From the NHS-Galleri Trial and PATHFINDER 2 Study to be Presented at 2026 American Society of Clinical Oncology (ASCO) Annual MeetingMENLO PARK, Calif., May 5, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the first quarter of 2026.

    5/5/26 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL to Announce First Quarter 2026 Financial Results

    MENLO PARK, Calif., April 22, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the first quarter 2026 following the close of market on Tuesday, May 5, 2026. Following the release, company management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress. First Quarter 2026 Webcast and Conference Call DetailsA link to the live webcast and recorded replay will be available at the investor

    4/22/26 4:01:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    GRAIL Reports Fourth Quarter and Full Year 2025 Financial Results

    Sold More Than 185,000 Galleri® Tests in 2025, Growing U.S. Galleri Revenue 26% Year-Over-Year to $136.8 MillionCompleted Galleri PMA Submission to FDAShared Topline Results from the NHS-Galleri TrialCompleted Analysis of the Full 35k Participant PATHFINDER 2 StudyStrong Financial Position with Cash into 2030MENLO PARK, Calif., Feb. 19, 2026 /PRNewswire/ -- GRAIL, Inc. (NASDAQ:GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today reported business and financial results for the fourth quarter and full year 2025 and provided business updates.

    2/19/26 4:02:00 PM ET
    $GRAL
    Medical Specialities
    Health Care

    $GRAL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/14/24 3:35:14 PM ET
    $GRAL
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by GRAIL Inc.

    SC 13G - GRAIL, Inc. (0001699031) (Subject)

    11/12/24 4:47:47 PM ET
    $GRAL
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by GRAIL Inc.

    SC 13G/A - GRAIL, Inc. (0001699031) (Subject)

    9/30/24 6:42:39 PM ET
    $GRAL
    Medical Specialities
    Health Care